You are here: Home » PTI Stories » National » News
Business Standard

Granules Hyderabad plant successfully closes USFDA inspection

Press Trust of India  |  New Delhi 

Pharma firm today said its Gagillapur facility in has completed USFDA inspection without any observations.

"The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed inspection without any observations," said in a filing.



"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."

The stock of was trading 2.29 per cent higher at Rs 122.75 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Granules Hyderabad plant successfully closes USFDA inspection

Pharma firm Granules India today said its Gagillapur facility in Hyderabad has completed USFDA inspection without any observations. "The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing. "This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)." The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE. Pharma firm today said its Gagillapur facility in has completed USFDA inspection without any observations.

"The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed inspection without any observations," said in a filing.

"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."

The stock of was trading 2.29 per cent higher at Rs 122.75 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Granules Hyderabad plant successfully closes USFDA inspection

Pharma firm today said its Gagillapur facility in has completed USFDA inspection without any observations.

"The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed inspection without any observations," said in a filing.

"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."

The stock of was trading 2.29 per cent higher at Rs 122.75 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard